Loading company
$550.55-0.1%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Past performance
- 1W
- +4.3%
- 1M
- +7.3%
- 3M
- +3.5%
- 6M
- +29.5%
- 1Y
- +27.1%
- 5Y
- +12.4%
Just reported
From Chemed's results release of October 27, 2026; its quarterly report has since been filed.
Actual
$690.9M
+11% y/y
+2.6% q/q
Guided
—
No guide given
Actual
$5.45
+22% y/y
+6.2% q/q
Guided
—
No guide given
Actual
$96.4M
+29% y/y
+8.1% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Built from Chemed Corp.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$550.55-0.1%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
The themes Chemed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
THCTenet Healthcare Corp.$22.8BA+
EHCEncompass Health Corporation$13.8BA+
ENSGEnsign Group, Inc.$10.9BA
PACSPACS Group, Inc.$7.6BA
CONConcentra Group Holdings Parent, Inc.$5.4BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade B+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Chemed Corp.’s grade history. The other 39 go back to November 2016.
